First-Quarter 2022 Earnings

Executing On Our Strategy Recent Highlights Demonstrating Ongoing Portfolio Resilience In Dynamic Environment¹ ▪ Operational sales growth of 3% and adjusted diluted EPS growth of 22% in Q1 2022 driven by improving rates of hospital admission and elective surgeries and the contribution from Hillrom Investing In Growth Opportunities And Executing On A Robust Pipeline Of Launches² ▪ Announced a long-term strategic partnership with Digital Diagnostics to offer its IDX-DR® autonomous Al software as a diagnostic service combined with the Welch Allyn RetinaVue 700 Imager ▪ Received U.S. FDA clearance of ST Set used in CRRT³; it has been available to customers in the U.S. since August 2020, when it received Emergency Use Authorization (EUA) from the FDA to provide CRRT to treat patients in an acute care environment during the COVID-19 pandemic ▪ Announced data indicating that the use of Sharesource remote patient management platform with an APD4 cycler may improve the clinical effectiveness of home kidney patients' care by extending their time on therapy by 3.4 months Delivering Enhanced Value For Shareholders ▪ Unwavering commitment to successfully integrating Hillrom, which brings together two leading, global medical technology innovators Paid quarterly dividend of $0.28 per share, reflecting strong financial position and commitment to returning value to shareholders Creating A Best Place To Work And Demonstrating Leadership In Corporate Social Responsibility ▪ Recently recognized by Forbes on its list of America's Best Large Employers 2022, based on employee ratings of factors such as working conditions, development opportunities and compensation ▪ Recently named to Forbes' Best Employers for Diversity 2022, which identifies companies most dedicated to diversity, equity and inclusion Baxter Accelerating Strategy Through Integration Of Hillrom To Advance Innovation, Expand Connected Care And Transform Healthcare ¹Non-GAAP financial metrics referenced in this slide include operational sales growth and adjusted diluted EPS growth. A reconciliation to comparable U.S. GAAP measures can be found herein and is available at www.baxter.com. 2See www.baxter.com for original press releases with additional product information. Continuous Renal Replacement Therapy. 4Automated Peritoneal Dialysis. CO 6

View entire presentation